Building a Transformational Gene Editing Therapeutics Company
Backdrop: Seminal research led by University of California Berkeley professor Jennifer Doudna described an elegant method to precisely edit any gene in any cell. This technology, called CRISPR/Cas9, has the potential to transform medicine by enabling therapies that directly modify disease-causing genes.
Atlas’ Role: Atlas co-founded Intellia with Caribou Biosciences. Atlas incubated Intellia from inception, co-led the Series A with Novartis, and Atlas entrepreneur-in-residence Nessan Bermingham became Intellia’s CEO. Atlas partner JF Formela helped to recruit Intellia’s executive team and craft large strategic partnerships with Novartis and Regeneron.
Today: Intellia raised over $100 million in its public offering (NASDAQ: NTLA) in May 2016, less than 2 years since the company’s formation. Intellia is advancing a broad pipeline of gene-editing therapies toward clinical development.